Clearmind Medicine says US publishes MDMA-PEA patent application for PTSD treatment

Reuters2026/08/24 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Clearmind reported U.S. publication of its patent application covering a combination of MDMA and N-acylethanolamines for treating PTSD.
Application also targets anxiety and eating disorders; palmitoylethanolamide cited as a lead N-acylethanolamine in the claimed methods.
Collaboration with NeuroThera integrates its PEA technology; partners now cite 13 joint patent applications filed globally.
Clearmind flagged potential to improve MDMA treatment economics via lower dosing, fewer side effects, and a wider therapeutic window.
Disclosure follows FDA final guidance dated July 13, 2026, outlining clinical development considerations for psychedelic drugs, including MDMA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240803PRIMZONEFULLFEED9814837) on August 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Clearmind Medicine says US publishes MDMA-PEA patent application for PTSD treatment

You may also like

Crypto prices